CN105412565A - Traditional Chinese medicine composition for treating cervical spondylosis - Google Patents
Traditional Chinese medicine composition for treating cervical spondylosis Download PDFInfo
- Publication number
- CN105412565A CN105412565A CN201510910531.9A CN201510910531A CN105412565A CN 105412565 A CN105412565 A CN 105412565A CN 201510910531 A CN201510910531 A CN 201510910531A CN 105412565 A CN105412565 A CN 105412565A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- radix
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/237—Notopterygium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/538—Schizonepeta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
Abstract
The invention discloses a traditional Chinese medicine composition for treating cervical spondylosis, and belongs to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition is prepared from radix ophiopogonis, herba schizonepetae, common clubmoss herb, Ipomoeapes-caprae(L.)R.Br.subsp.brasiliensis(L.)Oostst, notopterygium, panax notoginseng, eucommia ulmoides, rhizoma chuanxiong, rhizoma alismatis, tangerine peel and liquorice. The raw materials of the traditional Chinese medicine composition can be easily obtained, the traditional Chinese medicine composition is reasonable in composition and simple in preparation process, raw materials are easy to obtain, and it is proved through animal experiments and clinical experiments that the traditional Chinese medicine composition is remarkable in treatment effect on the aspect of treating cervical spondylosis, small in toxic and side effect, capable of dredging channels and activating qi and blood, and has a good health care and treatment effect on cervical spondylosis.
Description
Technical field
The invention belongs to technical field of Chinese medicines, relate to a kind of Chinese medicine composition for the treatment of cervical spondylosis.
Background technology
Cervical spondylosis is a kind of degeneration, refers to the Progressive symmetric erythrokeratodermia regression starting from single or multiple cervical intervertebral disk, and causes the bone of surrounding and the structural change of soft tissue, so the relevant blood vessel of impact, nerve root or (with) complication of spinal cord.Intervertebral disc degradation is the basic reason that cervical spondylosis occurs and develops, Unbalance cervical spondylosis
Animal model destroys muscle and the ligament of nape, makes sound Force system lose original balance, result in the regression of cervical intervertebral disk.In the developing of cervical spondylosis, chronic strain is primary arch-criminal, the damage of long-term local muscle, ligament, joint capsule, can cause local hemorrhage edema, be inflamed change, engenders inflammation machine at the position of pathological changes, and form hyperosteogeny, the nerve of impact local and blood vessel.
In addition, relevant research shows that the principle pathological mechanism of cervical spondylosis is " blood stasis ".Tired then obstructed, stagnation of QI and blood may bring about pain, congestion blocks, and QI and blood can not Ru Yangjinmai, not Rong Ze pain, therefore Patients with Cervical Spondylopathy often has neck shoulder and back ache, numb limbs and tense tendons, the performance of the blood addictions such as body of the tongue is dim, stringy pulse card.Research display congestion all can cause tissue blood fluid to reduce to organize congestion and edema with bowing, blood stasis add bow tissue change, blood flow reduce more obvious, and blood flow reduces and cervical spondylosis is proportionate, think that cervical vertebra regional flow decline (blood stasis) is major reason and the key link of cervical spondylosis morbidity.
At present, mainly there is operative treatment and non-operative treatment two kinds in the treatment of cervical spondylosis, and the shortcoming that operative treatment exists medical expense costliness, the refractory that takes stopgap measures originally, easily recurs, it is not the first-selection of Patients with Cervical Spondylopathy.In fact most cervical spondylosis case is all cured by non-operative treatment or is clearly better.Non-operative treatment comprises the methods such as Chinese and western drugs, acupuncture, massage, physical therapy, traction, and the medicine for the treatment of cervical spondylopathy comprises Western medicine and Chinese medicine two large divisions.If the drug main anti-inflammatory analgesic of western medicine cervical spondylopathy is main nonsteroidal analgesics, as chondroitin sulfate A, vitamin E, JINGTONGLING etc., such medicine is usually rapid-action, but effect is difficult to lastingly, needs long-term prescription; And the Chinese medicine clinical effectiveness of commercially available at present major part treatment cervical spondylosis is not good and drug effect is slow.
The patent of invention of disclosed treatment cervical spondylosis has a lot at present, such as: the Chinese medicine composition of the disclosed treatment cervical spondylosis of Chinese invention patent application 201410375462.1, comprise following raw materials: the Radix Astragali, Radix Glycyrrhizae, Radix Bupleuri, Herba Ephedrae, Rhizoma Chuanxiong, Caulis Spatholobi, Flos Carthami, Radix Cynanchi Auriculati, Radix Angelicae Sinensis, Radix Notoginseng, Radix Puerariae, the Radix Paeoniae Alba, Rhizoma Et Radix Notopterygii, Cortex Phellodendri, Radix Codonopsis, Olibanum, Flos Caryophylli, Cortex Cinnamomi, Rhizoma Curcumae Longae, Radix Saposhnikoviae, Semen Sinapis, Radix Angelicae Pubescentis, Crinis Carbonisatus, Semen Strychni, Herba Ephedrae, the Radix Angelicae Dahuricae, Rhizoma Sparganii, the Cortex Eucommiae, Radix Puerariae, Rhizoma Gastrodiae and Semen Persicae.This invention Chinese medicine composition prescription reaches kind more than 30, and composition is very complicated; And containing the multi-flavor such as Radix Cynanchi Auriculati, Herba Ephedrae rare Chinese medicine, the cost of this Chinese medicine composition is increased greatly.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of Chinese medicine composition for the treatment of cervical spondylosis and preparation method thereof, it is made to give full play to the opsonic action of Chinese medicine, there is significant therapeutic effect to cervical spondylosis, and be made into and facilitate easy-to-use finished product preparation, the rhythm of the modern life can be adapted to.
For realizing object of the present invention, the technical scheme of employing is as follows:
Treat a Chinese medicine composition for cervical spondylosis, be prepared from by the medical material of following weight portion: Radix Ophiopogonis 10-20 part, Herba Schizonepetae 8-20 part, Herba Lycopodii 10-20 part, Herba Ipomoeae Pes-Capraes 8-18 part, Rhizoma Et Radix Notopterygii 8-16 part, Radix Notoginseng 8-16 part, Cortex Eucommiae 6-14 part, Rhizoma Chuanxiong 8-14 part, Rhizoma Alismatis 6-14 part, Pericarpium Citri Reticulatae 4-8 part and Radix Glycyrrhizae 2-8 part.
In the scope of this weight portion, the comparatively significant formula of preferred 3 curative effects:
Formula 1: Radix Ophiopogonis 10 parts, Herba Schizonepetae 8 parts, Herba Lycopodii 10 parts, Herba Ipomoeae Pes-Capraes 8 parts, Rhizoma Et Radix Notopterygii 8 parts, Radix Notoginseng 8 parts, the Cortex Eucommiae 6 parts, Rhizoma Chuanxiong 8 parts, Rhizoma Alismatis 6 parts, Pericarpium Citri Reticulatae 4 parts and 2 parts, Radix Glycyrrhizae.
Formula 2: Radix Ophiopogonis 20 parts, Herba Schizonepetae 20 parts, Herba Lycopodii 20 parts, Herba Ipomoeae Pes-Capraes 18 parts, Rhizoma Et Radix Notopterygii 16 parts, Radix Notoginseng 16 parts, the Cortex Eucommiae 14 parts, Rhizoma Chuanxiong 14 parts, Rhizoma Alismatis 14 parts, Pericarpium Citri Reticulatae 8 parts and 8 parts, Radix Glycyrrhizae.
Formula 3: Radix Ophiopogonis 15 parts, Herba Schizonepetae 14 parts, Herba Lycopodii 14 parts, Herba Ipomoeae Pes-Capraes 14 parts, Rhizoma Et Radix Notopterygii 12 parts, Radix Notoginseng 12 parts, the Cortex Eucommiae 10 parts, Rhizoma Chuanxiong 10 parts, Rhizoma Alismatis 10 parts, Pericarpium Citri Reticulatae 6 parts and 5 parts, Radix Glycyrrhizae.
Correspondingly, the present invention also provides the preparation method of described Chinese medicine composition, comprises the following steps:
(1): get Radix Ophiopogonis and clean, crushed after being dried, cross 60-80 mesh sieve, the coarse powder obtained is placed in supercritical carbon dioxide extraction apparatus, the 30-45% volume fraction adding coarse powder weight is the ethanol of 60-85%, regulation and control carbon dioxide flow is 15-20L/h, extracting pressure is 15-20MPa, and extraction temperature is 40-60 DEG C, and extraction time is 1.5-2h, decompression separation obtains Radix Ophiopogonis extract, retains residue Radix Ophiopogonis;
(2): take Herba Schizonepetae, Herba Lycopodii, Herba Ipomoeae Pes-Capraes, Rhizoma Et Radix Notopterygii, Radix Notoginseng, the Cortex Eucommiae, Rhizoma Chuanxiong, Rhizoma Alismatis, Pericarpium Citri Reticulatae and Radix Glycyrrhizae respectively, decontamination, clean, dry, after section, be ground into coarse powder, for subsequent use;
(3): get (2) gained coarse powder, merge residue Radix Ophiopogonis, add the water soaking 3-4 hour of medical material total amount 8-10 times amount, then decoct 2-3 time, each 3-4 hour, filters and retains filtering residue, merging filtrate, filter vacuum surveys the concentrated solution that relative density is 1.05-1.15 under being evaporated to 60 DEG C of conditions, obtains water extracting liquid;
(4): in the filtering residue in (3), add medical material total amount 8-10 times amount volume fraction is the ethanol of 60-80%, reflux, extract, 2-3 time, each 4-6 hour, filter, merging filtrate, filter vacuum surveys the concentrated solution that relative density is 1.05-1.15 under being evaporated to 60 DEG C of conditions, obtains alcohol extraction concentrated solution;
(5): Radix Ophiopogonis extract, water extracting liquid and alcohol extraction concentrated solution are merged mixing, vacuum drying, pulverize, cross 100-200 mesh sieve, to obtain final product.
Further, the Chinese medicine composition of described treatment cervical spondylosis can be made into tablet, pill, powder, granule or capsule.
Source, the nature and flavor of Chinese prescription of the present invention Chinese crude drug used, return through and effect:
Radix Ophiopogonis: this product is the dried root of liliaceous plant Radix Ophiopogonis (dwarf lilyturf); Sweet in the mouth, micro-hardship, cold nature; GUIXIN, lung, stomach warp; YIN nourishing and the production of body fluid promoting, lung moistening clears away heart-fire.
Herba Schizonepetae: this product is the dry aerial parts of labiate Herba Schizonepetae; Acrid in the mouth, slightly warm in nature; Return lung, Liver Channel; Induce sweat loose wind, rash.
Herba Lycopodii: this product is the dry herb of lycopsid Lycopodium clavatum.Micro-hardship, pungent, warm in nature; Return liver,spleen,kidney warp; Expelling wind and removing dampness, relaxing muscles and tendons and activating QI and blood in the collateral.
Herba Ipomoeae Pes-Capraes: this product is Convolvulaceae morning glory two leaf Radix Ipomoeae, with all herbal medicine.Acrid in the mouth, micro-hardship, warm in nature; Expelling wind and removing dampness, detumescence of drawing out pus by applying a plaster to the affected part.
Rhizoma Et Radix Notopterygii: this product is dry rhizome and the root of samphire Rhizoma Et Radix Notopterygii (back of the body wing celery).Acrid in the mouth, hardship, warm in nature; Return bladder, kidney channel; Cold expelling, dispel the wind, dehumidify, pain relieving.
Radix Notoginseng: this product is the dry root of panax araliaceae plant; Sweet in the mouth, micro-hardship, warm in nature; Return liver, stomach warp; Dissipating blood stasis stops blooding, subduing swelling and relieving pain.
The Cortex Eucommiae: this product is the dry bark of the Eucommiaceae plant Cortex Eucommiae.Sweet in the mouth, warm in nature; Return liver, kidney channel; Invigorating the liver and kidney, bone and muscle strengthening, antiabortive.
Rhizoma Chuanxiong: this product is the dry rhizome of samphire Rhizoma Chuanxiong; Acrid in the mouth, warm in nature; Return liver, gallbladder, pericardium channel; Blood-activating and qi-promoting, wind-expelling pain-stopping.
Rhizoma Alismatis: this product is the dry tuber of Notes On Alism At Aceae Rhizoma Alismatis; Sweet in the mouth, cold in nature; Return kidney, urinary bladder channel; Diuresis, clearing away damp-heat.
Pericarpium Citri Reticulatae: this product is the dry mature skin of rutaceae orange and variety thereof; Bitter in the mouth, pungent, warm in nature; Return lung, spleen channel; Regulating qi-flowing for strengthening spleen, drying dampness to eliminate phlegm.
Radix Glycyrrhizae: this product is glycyrrhizic legume dry root; Sweet in the mouth, property is put down; GUIXIN, lung, spleen, stomach warp; Invigorating the spleen and replenishing QI, relieving spasm to stop pain, coordinating the actions of various ingredients in a prescription.
The compatibility analysis of Chinese medicine composition of the present invention:
Chinese medicine composition of the present invention with Herba Lycopodii and Herba Ipomoeae Pes-Capraes for monarch drug, expelling wind and removing dampness, relaxing muscles and tendons and activating QI and blood in the collateral, detumescence of drawing out pus by applying a plaster to the affected part; With Radix Ophiopogonis, Herba Schizonepetae, Rhizoma Et Radix Notopterygii, Radix Notoginseng and the Cortex Eucommiae for ministerial drug, induce sweat loose wind, and dissipating blood stasis stops blooding, subduing swelling and relieving pain; With Rhizoma Chuanxiong, Rhizoma Alismatis and Pericarpium Citri Reticulatae for adjuvant drug, blood-activating and qi-promoting, promoting the flow of QI-blood by warming the meridian, regulating qi-flowing for strengthening spleen; With Radix Glycyrrhizae for making medicine, invigorating the spleen and replenishing QI, relieving spasm to stop pain, the coordinating the actions of various ingredients in a prescription property of medicine.All medicines coordinate, and complement each other, synergism, has expelling wind and removing dampness, relaxing muscles and tendons and activating QI and blood in the collateral, subduing swelling and relieving pain, the effects such as promoting the flow of QI-blood by warming the meridian, have very significant curative effect to treatment cervical spondylosis.
Compared with prior art, Chinese medicine composition of the present invention has following advantage:
1, Chinese medicine composition of the present invention is made up of pure natural Chinese herbal medicine, all medicines work in coordination with, significantly reduce untoward reaction and toxic and side effects, have good effect, treating both the principal and secondary aspects of a disease, stress nurse one's health treatment advantage;
2, pharmacodynamics test data show, Chinese medicine composition of the present invention is more remarkable with the effect improving rat's blood stasis model blood rheology parameter at antiinflammatory, this shows that Chinese medicine composition of the present invention has significant synergism in treatment of cervical spondylopathy, significantly can improve the symptom of cervical spondylosis;
3, simple and easy to do, the efficacy stability of Chinese medicine composition preparation technology of the present invention, be easy to apply.
Therefore, the present invention's also application of claimed above-mentioned Chinese medicine composition in preparation treatment cervical spondylosis medicine.
Detailed description of the invention
Below will the present invention is described further by specific embodiment, it will be understood by those skilled in the art that the present invention also can make other similar changes and obtains similar result and do not depart from content of the present invention and scope except following examples.
embodiment 1
The agent of the embodiment of the present invention 1 Chinese medicinal composition capsules is prepared from by the medical material of following weight portion: Radix Ophiopogonis 10 parts, Herba Schizonepetae 8 parts, Herba Lycopodii 10 parts, Herba Ipomoeae Pes-Capraes 8 parts, Rhizoma Et Radix Notopterygii 8 parts, Radix Notoginseng 8 parts, the Cortex Eucommiae 6 parts, Rhizoma Chuanxiong 8 parts, Rhizoma Alismatis 6 parts, Pericarpium Citri Reticulatae 4 parts and 2 parts, Radix Glycyrrhizae.
Preparation method is as follows:
(1): get Radix Ophiopogonis and clean, crushed after being dried, cross 70 mesh sieves, the coarse powder obtained is placed in supercritical carbon dioxide extraction apparatus, 40% volume fraction adding coarse powder weight is the ethanol of 80%, regulation and control carbon dioxide flow is 18L/h, extracting pressure is 20MPa, and extraction temperature is 50 DEG C, and extraction time is 2h, decompression separation obtains Radix Ophiopogonis extract, retains residue Radix Ophiopogonis;
(2): take Herba Schizonepetae, Herba Lycopodii, Herba Ipomoeae Pes-Capraes, Rhizoma Et Radix Notopterygii, Radix Notoginseng, the Cortex Eucommiae, Rhizoma Chuanxiong, Rhizoma Alismatis, Pericarpium Citri Reticulatae and Radix Glycyrrhizae respectively, decontamination, clean, dry, after section, be ground into coarse powder, for subsequent use;
(3): get (2) gained coarse powder, merge residue Radix Ophiopogonis, add the water soaking 3 hours of medical material total amount 10 times amount, then decoct 3 times, each 3 hours, filter and retain filtering residue, merging filtrate, filter vacuum surveys the concentrated solution that relative density is 1.05-1.15 under being evaporated to 60 DEG C of conditions, obtains water extracting liquid;
(4): in the filtering residue in (3), add medical material total amount 8 times amount volume fraction is the ethanol of 70%, reflux, extract, 3 times, each 6 hours, filter, merging filtrate, filter vacuum surveys the concentrated solution that relative density is 1.05-1.15 under being evaporated to 60 DEG C of conditions, obtains alcohol extraction concentrated solution;
(5): Radix Ophiopogonis extract, water extracting liquid and alcohol extraction concentrated solution are merged mixing, vacuum drying, pulverize, cross 100 mesh sieves, obtain traditional Chinese medicine fine powder;
(6): add suitable adjuvant toward (5) gained traditional Chinese medicine fine powder, modern general preparation technique is utilized to make capsule.
embodiment 2
The agent of the embodiment of the present invention 2 Chinese medicinal composition capsules is prepared from by the medical material of following weight portion: Radix Ophiopogonis 20 parts, Herba Schizonepetae 20 parts, Herba Lycopodii 20 parts, Herba Ipomoeae Pes-Capraes 18 parts, Rhizoma Et Radix Notopterygii 16 parts, Radix Notoginseng 16 parts, the Cortex Eucommiae 14 parts, Rhizoma Chuanxiong 14 parts, Rhizoma Alismatis 14 parts, Pericarpium Citri Reticulatae 8 parts and 8 parts, Radix Glycyrrhizae.
Preparation method is with embodiment 1.
embodiment 3
The agent of the embodiment of the present invention 3 Chinese medicinal composition capsules is prepared from by the medical material of following weight portion: Radix Ophiopogonis 15 parts, Herba Schizonepetae 14 parts, Herba Lycopodii 14 parts, Herba Ipomoeae Pes-Capraes 14 parts, Rhizoma Et Radix Notopterygii 12 parts, Radix Notoginseng 12 parts, the Cortex Eucommiae 10 parts, Rhizoma Chuanxiong 10 parts, Rhizoma Alismatis 10 parts, Pericarpium Citri Reticulatae 6 parts and 5 parts, Radix Glycyrrhizae.
Preparation method is with embodiment 1.
pharmacodynamic study:
test example 1: Chinese medicine composition xylol of the present invention causes the impact of mice ear
1, experimental technique
Get healthy Kunming mouse 120, body weight is 22-26g, 8-12 week age, male and female half and half, be divided into 12 groups at random, often organize 10, be respectively: the high, medium and low dosage group of Chinese medicinal capsule that normal group, model group, ZHENGTIAN WAN positive drug control group (China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.), the embodiment of the present invention 1, embodiment 2, embodiment 3 are obtained.The dosage of high, medium and low dosage group is respectively 8g/Kg, 4g/Kg, 2g/Kg; Positive drug control group dosage is 8g/Kg, every day gavage 1 time, successive administration 1 month, cause ear at mouse right ear uniform application dimethylbenzene (0.05mL/ only) after last administration 60min to swell, measure respectively with calibrator again after medication 2h and record the thickness (μm) of mice bilateral ear, ear swelling value (μm)=auris dextra thickness-left ear thickness.
2, date processing
Data all adopt mean ± standard deviation to represent, adopt SPSS19.0 statistical software to carry out variance analysis,
p< 0.05 is for there being significant difference;
p< 0.01 is for there being pole significant difference.
3, experimental result
The impact of table 1 Chinese medicine composition xylol of the present invention induced mice ear swelling
Note: compared with normal group,
△ △ △ p< 0.001; Compared with model control group,
* p< 0.05,
* p< 0.01,
* * p< 0.001; Compared with positive controls,
# p< 0.05.
From upper table 1 result, after model group mice is subject to dimethylbenzene process ear thickness extremely significantly increase (
p< 0.001), therefore, it is possible to the effect of Chinese medicine composition of the present invention in antiinflammatory checked by the ear swelling model of application dimethylbenzene process.Compared with model group, the high, medium and low dosage group of embodiment 1, embodiment 2, embodiment 3 Chinese medicine composition and positive drug control group all have significant therapeutic effect (
p< 0.05), wherein, after the treatment of Chinese medicine composition high dose group, the ear swelling of mice recovers normal level substantially, reaches the effect of curing completely; The therapeutic effect of Chinese medicine composition high dose be all better than positive control drug (
p< 0.05), this shows that Chinese medicine composition of the present invention has significant antiinflammatory action, for can the inflammatory conditions of fundamentally reduction of patient during treatment of cervical spondylopathy.
test example 2: Chinese medicine composition of the present invention is to the improvement result of rat blood stasis models
1, experimental technique
Get healthy Wistar rat, body weight 200-220g, 120, male and female half and half, be divided into 12 groups at random, often organize 10, be divided at random: normal group, model group, positive drug control group (ZHENGTIAN WAN, the accurate word Z44020711 of traditional Chinese medicines, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.), the obtained high, medium and low dosage group of Chinese medicinal capsule of the embodiment of the present invention 1, embodiment 2, embodiment 3.The dosage of high, medium and low dosage group is respectively 4g/Kg, 2g/Kg, 1g/Kg; Positive drug control group dosage is 4g/Kg; Normal group and model group to 0.5%CMC, every day gavage 2 times, successive administration 20 days.The 20th day of gastric infusion, except Normal group, all the other treated animals press 1mg/Kg subcutaneous injection adrenalin hydrochloride, 2 times/day, interval 4h, put animal in 4 DEG C of frozen water ice bath 15min after first time injection 3h.Injection hydrochloric acid is got 4-5ml blood anticoagulant heparin for adrenergic 3rd day and is measured blood rheology parameter, gets liver and to weigh conversion organ coefficient.
2, date processing
Data all adopt mean ± standard deviation to represent, adopt SPSS19.0 statistical software to carry out variance analysis,
p< 0.05 is for there being significant difference;
p< 0.01 is for there being pole significant difference.
3, experimental result:
Table 2 Chinese medicine composition of the present invention is on the impact of rat blood stasis models lectin from hemolymph
Note: compared with normal group,
△ △ p< 0.01; Compared with model group,
* p< 0.05,
* p< 0.01,
* * p
< 0.001; Compare with positive controls,
# p< 0.05.
Table 2 result shows, compares with normal control, the whole blood height cut index of model group, the low cut index of whole blood, erythrocyte aggregation index, Casson viscosity and plasma viscosity all have and significantly increase (
p< 0.05), the success of rat blood stasis models model construction is described.Compare with model group, after basic, normal, high three the dosage groups of medicinal tablet that the embodiment of the present invention 1, embodiment 2, embodiment 3 are obtained and positive controls medication all significantly or pole reduce whole blood height cut index, the low cut index of whole blood, erythrocyte aggregation index, Casson viscosity and plasma viscosity significantly, wherein high dose all have pole significant difference (
p< 0.01).Under same experiment condition, positive control drug group therapeutic effect is all not as good as medicinal tablet high dose group of the present invention.
chinese medicine composition of the present invention is to the clinical observation on the therapeutic effect of cervical spondylosis clinical volunteers patient
1, basic document:
Choose 400 routine cervical spondylosis clinical volunteers patients, the age is 20-55 year, and the mean age is 36 years old, and wherein the course of disease is the longest is 8 years, and the shortest is June; Confirm have cervical vertebrae physiological lordosis to disappear or processus aboralis through CT and X-ray, stenosis of disc space, the performances such as ligamentum nuchae ossification, patient may feel that cervical region is heavy, sour, swollen, stiff, the acid of companion upper limb side is swollen unable, there is chronic seizures cervical vertebra with shoulder arm numb pain, or have that dizziness, vision are unclear or to play face morning impractical, arm swelling etc.Be divided into 4 groups at random, be respectively matched group, treatment A group, treatment B group and treatment C group, often organize 100 examples, each group at age, sex, coincident with severity degree of condition without too big-difference, there is comparative.
2, Therapeutic Method:
Matched group: take ZHENGTIAN WAN (China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.), every day 2 times, 1 ball 7 days is a course for the treatment of, totally 4 courses for the treatment of.
Treatment A group, B group and component C do not take the obtained capsule of the embodiment of the present invention 1,2 and 3, and every day 2 times, each 27 days is a course for the treatment of, totally 4 courses for the treatment of.
3, criterion of therapeutical effect:
Recovery from illness: after medication, various cervical spondylosis symptom and sign disappear, neck, shoulder, the exhibition activity of forearm Shen obviously freely, functional rehabilitation, the transference cures such as visual disorder, do not recur after following up a case by regular visits to 1 year;
Effective: after medication, cardinal symptom and sign disappear substantially, most of functional rehabilitation, does not recur after following up a case by regular visits to 1 year;
Effective: after medication, cardinal symptom alleviates basic function recovery a little, the drug withdrawal later six months of recidivist again;
Invalid: before and after treatment, symptom and sign are without change.
Total effective rate=(curing number+effective number+significant figure) total number of cases × 100% of/patient.
4, therapeutic outcome:
Table 3 clinical therapeutic efficacy
Can be found out by upper table 3, the cure rate of Chinese medicine composition of the present invention reaches 80%, and total effective rate reaches 85%, and far above matched group cure rate and total effective rate, wherein to treat the best results of C group and embodiment 3, its cure rate is 84%, and total effective rate reaches 93%.Each group of patient has no untoward reaction during clinical treatment, and after treatment, the mental status is good, functional rehabilitation, illustrates that Chinese medicine composition of the present invention has the advantage of its uniqueness in treatment cervical spondylosis, safe and effective, has clinical generalization value.
Claims (5)
1. treat the Chinese medicine composition of cervical spondylosis for one kind, it is characterized in that, described Chinese medicine composition is prepared from by the medical material of following weight portion: Radix Ophiopogonis 10-20 part, Herba Schizonepetae 8-20 part, Herba Lycopodii 10-20 part, Herba Ipomoeae Pes-Capraes 8-18 part, Rhizoma Et Radix Notopterygii 8-16 part, Radix Notoginseng 8-16 part, Cortex Eucommiae 6-14 part, Rhizoma Chuanxiong 8-14 part, Rhizoma Alismatis 6-14 part, Pericarpium Citri Reticulatae 4-8 part and Radix Glycyrrhizae 2-8 part.
2. the Chinese medicine composition for the treatment of cervical spondylosis according to claim 1, it is characterized in that, described Chinese medicine composition is prepared from by the medical material of following weight portion: Radix Ophiopogonis 10 parts, Herba Schizonepetae 8 parts, Herba Lycopodii 10 parts, Herba Ipomoeae Pes-Capraes 8 parts, Rhizoma Et Radix Notopterygii 8 parts, Radix Notoginseng 8 parts, the Cortex Eucommiae 6 parts, Rhizoma Chuanxiong 8 parts, Rhizoma Alismatis 6 parts, Pericarpium Citri Reticulatae 4 parts and 2 parts, Radix Glycyrrhizae.
3. the Chinese medicine composition for the treatment of cervical spondylosis according to claim 1, it is characterized in that, described Chinese medicine composition is prepared from by the medical material of following weight portion: Radix Ophiopogonis 20 parts, Herba Schizonepetae 20 parts, Herba Lycopodii 20 parts, Herba Ipomoeae Pes-Capraes 18 parts, Rhizoma Et Radix Notopterygii 16 parts, Radix Notoginseng 16 parts, the Cortex Eucommiae 14 parts, Rhizoma Chuanxiong 14 parts, Rhizoma Alismatis 14 parts, Pericarpium Citri Reticulatae 8 parts and 8 parts, Radix Glycyrrhizae.
4. the Chinese medicine composition for the treatment of cervical spondylosis according to claim 1, it is characterized in that, described Chinese medicine composition is prepared from by the medical material of following weight portion: Radix Ophiopogonis 15 parts, Herba Schizonepetae 14 parts, Herba Lycopodii 14 parts, Herba Ipomoeae Pes-Capraes 14 parts, Rhizoma Et Radix Notopterygii 12 parts, Radix Notoginseng 12 parts, the Cortex Eucommiae 10 parts, Rhizoma Chuanxiong 10 parts, Rhizoma Alismatis 10 parts, Pericarpium Citri Reticulatae 6 parts and 5 parts, Radix Glycyrrhizae.
5. the Chinese medicine composition of the treatment cervical spondylosis according to any one of claim 1-4, is characterized in that: described Chinese medicine composition is made into tablet, pill, powder, granule or capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510910531.9A CN105412565A (en) | 2015-12-10 | 2015-12-10 | Traditional Chinese medicine composition for treating cervical spondylosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510910531.9A CN105412565A (en) | 2015-12-10 | 2015-12-10 | Traditional Chinese medicine composition for treating cervical spondylosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105412565A true CN105412565A (en) | 2016-03-23 |
Family
ID=55491412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510910531.9A Pending CN105412565A (en) | 2015-12-10 | 2015-12-10 | Traditional Chinese medicine composition for treating cervical spondylosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105412565A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106039045A (en) * | 2016-06-23 | 2016-10-26 | 孙丰卿 | Traditional Chinese medicine compound for treating cervical spondylosis and preparation method for preparation |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104027409A (en) * | 2013-03-05 | 2014-09-10 | 赵银香 | Chinese medicinal composition for treatment of cervical vertebra diseases |
| WO2014188214A1 (en) * | 2013-05-24 | 2014-11-27 | Susan Jane Branch | Topical composition with ginger |
-
2015
- 2015-12-10 CN CN201510910531.9A patent/CN105412565A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104027409A (en) * | 2013-03-05 | 2014-09-10 | 赵银香 | Chinese medicinal composition for treatment of cervical vertebra diseases |
| WO2014188214A1 (en) * | 2013-05-24 | 2014-11-27 | Susan Jane Branch | Topical composition with ginger |
Non-Patent Citations (2)
| Title |
|---|
| 曾品涛等: "超临界CO2萃取麦冬中高异黄酮类物质的工艺研究", 《中国药业》 * |
| 洪杰等: "《常见病简明药浴疗法》", 31 August 2013, 吉林科学技术出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106039045A (en) * | 2016-06-23 | 2016-10-26 | 孙丰卿 | Traditional Chinese medicine compound for treating cervical spondylosis and preparation method for preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103386008B (en) | Chinese medicine composition for treating endocrine dyscrasia | |
| CN103961424A (en) | Traditional Chinese medicine formula for treating cervical spondylosis and preparation method of traditional Chinese medicine capsule preparation | |
| CN103316141A (en) | Traditional Chinese medicine composition for treating cervical spondylosis | |
| CN104887747A (en) | Traditional Chinese medicine composition for treating cerebral thrombosis and preparation method therefor | |
| CN104306891A (en) | Traditional Chinese medicine for treating neurasthenia | |
| CN105311140A (en) | Pharmaceutical composition for treating cervical spondylosis and preparation method thereof | |
| CN105582274A (en) | Pharmaceutical composition for treating female climacteric syndrome and preparing method thereof | |
| CN104958429A (en) | Traditional Chinese medicinal composition for treating geriatric fracture and preparation method thereof | |
| CN102100849B (en) | Chinese medicine preparation for treating lumbar disc herniation and preparation method thereof | |
| CN104189478A (en) | Traditional Chinese medicine composition for treating cervical spondylosis and preparation method thereof | |
| CN105412565A (en) | Traditional Chinese medicine composition for treating cervical spondylosis | |
| CN105362648A (en) | Method for preparing traditional Chinese medicine composition for treating cervical spondylosis | |
| CN100515462C (en) | Chinese medicine for treating cardiovascular and cerebrovascular trrombus and preparing method | |
| CN103446386A (en) | Traditional Chinese medicine composition for treating lumbago | |
| CN108578603B (en) | Traditional Chinese medicine compound for treating kidney deficiency and marrow depletion type knee osteoarthritis based on shaoyang bone governing theory and application thereof | |
| CN105434799A (en) | Method for preparing traditional Chinese medicine composition for treating geriatric fracture | |
| CN105395711A (en) | Traditional Chinese medicine preparation for treating cervical spondylosis and preparation method thereof | |
| CN105535817A (en) | A traditional Chinese medicine composition containing argy wormwood leaves and used for treating cervical spondylosis and a preparing method thereof | |
| CN103393961B (en) | Traditional Chinese medicine for treating cervical spondylosis and preparation method thereof | |
| CN110841007B (en) | Traditional Chinese medicine composition for treating cerebral apoplexy sequela and application thereof | |
| CN114504635B (en) | Chinese patent medicine for treating apoplexy sequela | |
| CN102579722B (en) | Chinese medicinal composition for treating femoral head necrosis and preparation method thereof | |
| CN105288086A (en) | Traditional Chinese medicine composition for treating cerebral thrombosis and preparing method thereof | |
| CN105194299A (en) | Application of traditional Chinese medicine composition in preparation of medicines for treating cerebral thrombosis | |
| CN104547865A (en) | Application of traditional Chinese medicine preparation in preparing medicine for treating senile dementia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160323 |